Fig 1: The effects of YB or CE on BMDCs: (A) the percentage of CD80/86-positive cells in CD11c+ BMDCs treated with YB (3.7 μg/mL) or cellulose (CE, Lo: 1 μg/mL; Hi: 2 μg/mL) (n = 3). (B) The expression of MHC-II in CD11c+ BMDCs treated with YB or CE (n = 4). (C) The concentrations of interleukin (IL)-12, p40, and IL-6 in the culture supernatant of BMDCs in the presence or absence of lipopolysaccharide (LPS: 10 ng/mL, as a positive control), YB (3.7 μg/mL), or CE (2 μg/mL) (n = 3). (D,E) The effects of YB (0–3.7 μg/mL) on Th1 differentiation in naïve CD4+ T cells co-cultured with BMDCs (n = 4). Recombinant IL-12 (10 ng/mL) was used as a positive control for Th1 differentiation. Cytokine concentrations were measured by fluorescence-activated cell sorting using CBA. Values and error bars indicate the means ± SD. Dunnett’s multiple comparison test was used for statistical analysis. * p < 0.05; ** p < 0.01; *** p < 0.001 versus CT.
Fig 2: Combined treatment of Vancomycin-Loaded Calcium Sulfate and negative pressure drainage apparatus for combating open fracture infection. Note: (A) Percentage of lymphocytes and neutrophils in mouse blood on the 5th day of MRSA infection analyzed by CBC blood routine analysis. (B) Levels of G-CSF, IL-6, IL-12 (p40), and IL-12 (p70) in mouse serum detected by ELISA. (C) Safranin O staining of cartilage formation in mouse groups (Scar Bar = 1000 μm). (D) Bacterial CFU in mouse joint tissue detected by bacterial culture. (E) X-ray detection of skeletal repair in mouse joints. (F) H&E staining of tissue damage in mouse fractures (Scar Bar = 1000 μm). (G) Expression of MBD2 protein in mouse fracture tissues detected by WB. (H) Expression of M1 and M2 macrophage markers in mouse fracture tissues detected by WB. (I) Proportion of M2 macrophages (CD206 + CD11b+) in mouse fracture tissues detected by flow cytometry. * indicates p < 0.05 compared to the Sterile fracture or MRSA group. n = 6
Supplier Page from Abcam for Mouse IL-12 p40 ELISA Kit